| Local BLyS production by T follicular cells mediates retention of high affinity B cells during affinity maturation R Goenka, AH Matthews, B Zhang, PJ O’Neill, JL Scholz, TS Migone, ... Journal of Experimental Medicine 211 (1), 45-56, 2014 | 134 | 2014 |
| Targeted inhibition of CD47-SIRPα requires Fc-FcγR interactions to maximize activity in T-cell lymphomas S Jain, A Van Scoyk, EA Morgan, A Matthews, K Stevenson, G Newton, ... Blood, The Journal of the American Society of Hematology 134 (17), 1430-1440, 2019 | 57 | 2019 |
| Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia AH Matthews, AE Perl, SM Luger, AW Loren, SI Gill, DL Porter, ... Blood Advances 6 (13), 3997-4005, 2022 | 47 | 2022 |
| Homeostatic control of B lymphocyte subsets JE Crowley, JL Scholz, WJ Quinn III, JE Stadanlick, JF Treml, LS Treml, ... Immunologic research 42, 75-83, 2008 | 44 | 2008 |
| Bleeding risk by intensity of anticoagulation in critically ill patients with COVID‐19: a retrospective cohort study R Halaby, A Cuker, J Yui, A Matthews, E Ishaaya, E Traxler, C Domenico, ... Journal of Thrombosis and Haemostasis 19 (6), 1533-1545, 2021 | 29 | 2021 |
| Mistaken identity: frequency and effects of gender-based professional misidentification of resident physicians S Berwick, H Calev, A Matthews, A Mukhopadhyay, B Poole, J Talan, ... Academic Medicine 96 (6), 869-875, 2021 | 19 | 2021 |
| Refractory lactic acidosis in small cell carcinoma of the lung DJ Oh, E Dinerman, AH Matthews, AW Aron, KM Berg Case Reports in Critical Care 2017 (1), 6148350, 2017 | 8 | 2017 |
| Optimizing outcomes in secondary AML A Matthews, KW Pratz Hematology 2022 (1), 23-29, 2022 | 7 | 2022 |
| Real world survival outcomes of CPX-351 versus venetoclax and azacitadine for initial therapy in adult acute myeloid leukemia A Matthews, AE Perl, SM Luger, DV Babushok, NV Frey, S Gill, ... Blood 138, 795, 2021 | 7 | 2021 |
| Receiving real-time clinical feedback: a workshop and OSTE assessment for medical students A Matthews, M Hall, JM Parra, MM Hayes, CP Beltran, BL Ranchoff, ... Advances in Medical Education and Practice, 861-867, 2020 | 7 | 2020 |
| Real‐world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia AH Matthews, AE Perl, SM Luger, SI Gill, C Lai, DL Porter, S Skuli, ... American journal of hematology 98 (8), 1254-1264, 2023 | 5 | 2023 |
| Targeting Menin and CD47 to address unmet needs in acute myeloid leukemia AH Matthews, KW Pratz, MP Carroll Cancers 14 (23), 5906, 2022 | 3 | 2022 |
| Real World Effectiveness of 7+ 3 Intensive Chemotherapy Vs Venetoclax and Hypomethylating Agent for Initial Therapy in Adult Acute Myeloid Leukemia A Matthews, AE Perl, SM Luger, S Gill, C Lai, DL Porter, S Skuli, XJ Bruno, ... Blood 140 (Supplement 1), 1022-1024, 2022 | 3 | 2022 |
| Post-transplant frailty phenotype predicts survival AD Hadjis, GW White, SI Gill, N Hossain, NV Frey, EO Hexner, XJ Bruno, ... Transplantation and Cellular Therapy, Official Publication of the American …, 2024 | 2 | 2024 |
| Cerebral Infarction due to Severe ADAMTS-13 Deficiency with Normal Hematological Parameters: A Potential Cause of Cryptogenic Stroke A Matthews, J Yui, EY Chiang, AM Pishko, A Cuker, BL Cucchiara, ... Journal of Stroke and Cerebrovascular Diseases 31 (6), 106431, 2022 | 2 | 2022 |
| Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real‐world data from eight US … Y Abaza, ES Winer, GSG Murthy, RM Shallis, AH Matthews, T Badar, ... American journal of hematology 99 (4), 606-614, 2024 | 1 | 2024 |
| Frail and pre-frail older adults with acute myeloid leukemia have inferior survival due to higher rates of disease-related deaths AD Hadjis, GW White, C Catania, NV Frey, S Gill, EO Hexner, XJ Bruno, ... Blood 142, 376, 2023 | 1 | 2023 |
| A multi-center retrospective review of COVID-19 outcomes in patients with lymphoid malignancy Y Choi, J Caro, X Li, A Al-Obeidi, SL Kurtz, AI Kim, JE Chang, ... Blood 138, 184, 2021 | 1 | 2021 |
| Chemoresistance of TP53 mutant AML requires the mevalonate byproduct, GGPP, for regulation of ROS and induction of a mitochondria stress response SJ Skuli, AI Bakayoko, M Kruidenier, B Manning, P Pammer, A Salimov, ... bioRxiv, 2024.06. 07.597976, 2024 | | 2024 |
| Immunohistochemistry-based detection of TP53 mutations in acute myeloid leukemia: a promising high sensitivity diagnostic approach A Matthews, E Fenu, SJ Skuli, JC Harris, C Lai Leukemia & Lymphoma, 1-4, 2024 | | 2024 |
